YMYing Ma

Ying Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ying Ma has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Dan Zhao

    Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, 16 Hepingli Middle St, Dongcheng District, Beijing, 100013, China, 86 01064407095

    1 shared publication
  • Jiang Wu

    Beijing Center for Disease Prevention and Control, No. 16, Hepingli Middle Street, Dongcheng District, Beijing 100013, China

    1 shared publication
  • Juan Li

    Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, 16 Hepingli Middle St, Dongcheng District, Beijing, 100013, China, 86 01064407095

    1 shared publication
  • Luodan Suo

    Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, 16 Hepingli Middle St, Dongcheng District, Beijing, 100013, China, 86 01064407095

    1 shared publication
  • Wei Yao

    Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, 16 Hepingli Middle St, Dongcheng District, Beijing, 100013, China, 86 01064407095

    1 shared publication
  • Xiaomei Li

    Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, 16 Hepingli Middle St, Dongcheng District, Beijing, 100013, China, 86 01064407095

    1 shared publication

Latest Publications

  • Open Access

    Effectiveness of Inactivated COVID-19 Vaccination Against COVID-19–Related Hospitalization and Severe Outcomes in Adults ≥80 Years During Omicron Circulation in Beijing, China: Retrospective Cohort Study

    by Dan Zhao, Ying Ma, Juan Li, Xiaomei Li, Zhiqiang Cao, Wei Yao, Jiang Wu, Luodan Suo

    Background: A large wave of COVID-19 caused by SARS-CoV-2 Omicron subvariants began in Beijing in early December 2022. Objective: This study aimed to evaluate the COVID-19 vaccine effectiveness (VE) in mitigating the risk of COVID-19–related hospitalization during the epidemic. Methods: We conducted a retrospective cohort study linking regional health care data and vaccination registry routinely collected in Beijing. All electronic medical records on COVID-19–related hospital discharges of older inpatients aged ≥80 years during November 2022 and February 2023 were included. Poisson regressions were used to estimate incidence risk ratio of COVID-19–related hospitalization, severe or critical cases, and in-hospital death compared with unvaccinated groups, adjusting for gender and age. VE was calculated as 1 minus incidence risk ratio×100%. Results: A total of 53,789 individuals aged ≥80 years were included, 28,423 (52.84%) were male, 45,270 (84.16%) were aged 80‐89 years, and 8519 (15.84%) were aged ≥90 years. Overall, 30,531 (56.76%) were in the vaccine group, with 4524 (8.41%) of the total participants receiving partial vaccination, 20.91% completing the primary series, and 14,761 (27.44%) receiving one booster. Additionally, 23,258 (43.24%) were in the unvaccinated group. Of the 53,789 hospitalized individuals, 17,916 (33.31%) had a COVID-19 diagnosis, 3535 (6.57%) had COVID-19–related hospitalization, 961 (1.79%) were COVID-19 severe or critical cases, and 4130 (7.68%) had in-hospital death. The analysis revealed that the VE of booster vaccination in preventing COVID-19–related hospital, severe or critical COVID-19, and in-hospital death was 63.5% (95% CI 59.8%‐66.9%), 66.9% (95% CI 60.1%‐72.6%) and 79.4% (95% CI 77%‐81.5%), the VE of primary series 56% (95% CI 51.4%‐60.2%), 66.8% (95% CI 59%‐73%) and 66.4% (95% CI 63%‐69.5%). Conclusions: The first booster vaccination was associated with significantly reduced the risk of COVID-19–related severe outcomes in older inpatients aged ≥80 years during the Omicron-dominant period. Considering the potential selection bias and unmeasured confounders, these estimates may reflect both the VE and the better baseline health status of the vaccinated older individuals.